A Unique Learning Platform
The ILCA School of Liver Cancer aims at delivering scientific education and helping progress ILCA’s mission to advance research in pathogenesis, prevention and treatment of liver cancer.
The ILCA School is a unique learning platform for practitioners and investigators to receive education in an intense, interactive and multidisciplinary format.
This annual educational event consists of 1,5 day courses focusing on a specific topic and is hosted in a Centre of Excellence worldwide which is selected based on application.
The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.
Participants learn about the principles and nuances of the diagnosis, management, and clinical investigation of liver cancer. The School’s intense, multidisciplinary and interactive format offers attendees state-of-the-art clinically relevant information regarding the disease.
- A residential, didactic and interactive format
- Dedicated time for one on one exchanges with a distinguished faculty and key opinion leaders
- A balanced seminar format involving multidisciplinary faculty
- Case-based examples for discussion emphasis
Fellows in gastroenterology and hepatology training programmes, junior faculty, basic/translational researchers and experienced clinicians with a desire to become more involved in liver cancer investigation and care.
ILCA School Paris, France, 11 – 12 December 2020
The next ILCA School of Liver Cancer will take place in Paris!
ILCA is very pleased to announce that the next edition of the ILCA School of Liver Cancer will take place in Paris, it will be hosted by The Cordeliers Research Center on 11−12 December 2020.
The Cordeliers Research Centre (CRC, Centre de recherche des Cordeliers) is a research center of excellence located in the center of Paris, in the academic heart of Paris on a historical site. CRC develops fundamental, translational and clinical research in the field of biology and health. Research projects are multidisciplinary, mainly in the fields of oncology, immunology, the study of metabolism and the major physiological functions of the body.
|Friday, 11 December|
|Risk factors, screening and diagnosis of HCC: What is new?
(Chair: Valérie Paradis, Beaujon)
|08:30 – 08:40||Welcome Remarks|
|08:40 – 09:00||Perspective on epidemiology and HCC screening in the era of NASH
Nathalie Ganne-Carrie (Bobigny)
|09:00 – 09:30||Understanding the physiopathology of NASH related HCC
Mathias Heikenwalder (Heidelberg, DFKZ)
|09:30 – 09:50||Update on the Imaging Diagnosis of HCC
Alain Luciani (Mondor)
|09:50 – 10:10||The future of HCC pathology
Julien Calderaro (Mondor)
|10:10 – 10:40||Blast session on hot topics: controversies in HCC screening and diagnosis (two 10 minute presentations + 10 minute discussion)
Pierre Nahon (Bobigny) Impact of antiviral treatment on tumor occurrence and recurrence
François Durand (Beaujon) Why and how to assess non-tumor liver in HCC patients?
|10:40 – 11:00||Coffee Break|
|Management of early stage HCC: can we go beyond guidelines ?
(Chair: Michel Beaugrand, Bobigny)
|11:00 – 11:30||A multidisciplinary approach of a case
H(Panel: Daniel Cherqui, Valérie Paradis, Olivier Seror, Jordi Bruix)
Presetation of case report Manon Allaire (Pitié-Salpétrière): A small HCC with aggressive features
|11:30 – 12:00||Non-invasive biomarkers in HCC
Augusto Villanueva (Mont Sinai)
|12:00 – 12:20||Why and how to expend criteria for surgery
Eric Vibert (Paul Brousse)
|12:20 – 12:40||Current knowledge and innovation in percutaneous treatment of HCC
Olivier Seror (Bobigny)
|12:40 – 13:10||Blast session on hot topic: can we improve treatment of early HCC ? (two 10 minute presentations + 10 minute discussion)
The place of mini invasive surgery : short term advantages and bridge to liver transplantation Olivier Scatton (Pitié-Salpétrière)
Can we expend criteria of liver transplantation beyond composite criteria? Christophe Duvoux (Mondor)
|13:10 – 14:00||Lunch Break|
|14:00 – 14:30||State of the art: Jessica Zucman-Rossi (Cordeliers research center) Genomic of hepatocellular carcinoma
Chair: Gregory Gores, Mayo Clinic
|Evidence and doubt about management of Intermediate HCC
Chair: Gregory Gores, Mayo Clinic
|14:30 – 15:00||A multidisciplinary approach of a case
(Panel: René Adam, Valérie Vilgrain,Christophe Duvoux, Tim Meyer
|15:00 – 15:20||Current knowledge of endovascular treatment of HCC (except SIRT
Thierry De Baere (Institut Gustave Roussy)
|15:20 – 15:40||Assessment of radiological response: conventional and functional imaging of HCC
Maxime Ronot (Beaujon)
|15:40 – 16:10||Blast session on hot topics: role of SIRT in 2020
Julien Edeline (Rennes) : SIRT ProTim Meyer (Royal Free Hospital): SIRT Against
|16:10 – 16:40||Coffee Break|
|Present and future of advanced HCC: targeted therapy
(Chair: Sandrine Faivre, Saint Louis Hospital)
|16:40 – 17:00||Preclinical models of HCC and prediction of therapeutic response
Sandra Rebouissou (Cordeliers research center)
|17:00 – 17:30||Current and future role of targeted therapy in the management of advanced HCC
Peter Galle (Mainz)
|17:30 – 18:00|| Blast session on hot topics: improving results of targeted therapy
Potential role of combination therapy in HCC
Olivier Rosmorduc (Paul Brousse)Reason of failure and success of phase 3 randomized controlled trial
Sandrine Faivre (Saint Louis)
|Saturday, 12 December|
|Present and future of advanced HCC: immunotherapy
(Chair: Tim Meyer, Royal Free Hospital)
|08:30 – 09:00||Basic immunology in liver carcinogenesis for dummies
Amaia Lujambio (Mont Sinai)
|09:00 – 09:20||Immunotherapy of HCC hope and hype
Thomas Decaens (Grenoble)
|09:20 – 09:50||Blast session on hot topics: new questions rise with immunotherapy
Can we identify predictor of response to immunotherapy ? The immuno-oncologist point of view
Stéphane Champiat (Institut Gustave Roussy)Management of adverse events of immunotherapy
Mohamed Bouattour (Beaujon)
|09:50 – 10:20||State of the Art: Pr Jordi Bruix Classification and treatment of HCC: a historical perspective
Chair: Tim Meyer
|10:20 – 11:00||Coffee Break|
|The cholangiocarcinoma session
(Chair: Augusto Villanueva, Mont Sinai)
|11:00 – 11:30||A multidisciplinary approach of a case (Panel: Eric Vibert, Thierry De Baere, Sandrine Faivre, Gregory Gores)
Presentation of case report Marie Lequoy (Saint Antoine): cholangiocarcinoma
|11:30 – 12:00||Pathogenesis of cholangiocarcinoma and cell of origin
Lars Zender (University of Tubingen)
|12:00 – 12:20||Primary liver cancers and mixed tumors: a continuum ? the molecular biologist/pathologist point of view
Valérie Paradis (Beaujon)
|12:20 – 12:50||The moving field of systemic treatment of cholangiocarcinoma
Gregory Gores (Mayo Clinic)
|12:50 – 13:20||Blast session on hot topics: what is the best option for curative treatment of intrahepatic and extrahepatic cholangiocarcinoma ?Olivier Soubrane (Beaujon): Resection
Emmanuel Boleslaswki (Lille): Transplantation
|13:20 – 13:30||Closing Remarks
Jean-Charles Nault (Bobigny), Eric Vibert (Paul brousse)
Registration for ILCA School 2020 will open soon
Venue & Accommodation
The venue of the ILCA School of Liver Cancer 2020 is the Centre de Recherche des Cordeliers in Paris, France.
Centre de Recherche des Cordeliers, 15 Rue de l’École de Médecine, 75006 Paris, France
The ILCA School of Liver Cancer is supported by an unrestricted educational grant from Bristol-Myers Squibb